FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2047815134> ?p ?o ?g. }

• W2047815134 endingPage "A208" @default.
• W2047815134 startingPage "A208" @default.
• W2047815134 abstract "Abstract Insulin-like growth factor (IGF) signaling is thought to play an important role in the development of tumors and resistance to existing cancer therapies. The proliferative and pro-survival signals driven by the IGF ligands, IGF-1 and IGF-2, are transmitted through their binding to the IGF-1 receptor (IGF-1R). In addition, IGF-2 activates the insulin receptor variant A (IR-A) that is expressed during embryonic development as well as in many cancers. To target IGF signaling for cancer therapy we have developed BI 836845, a fully human IgG1 antibody derived from an antibody phage display library that can bind to and neutralize the functions of both IGF-1 and IGF-2. Surface plasmon resonance (Biacore) analysis demonstrated that BI 836845 has an affinity (KD) of 0.07 nM and 0.8 nM for human IGF-1 and IGF-2, respectively. BI 836845 also shows comparable affinities to mouse as well as rat IGF-1 and IGF-2, allowing a comprehensive pre-clinical characterization of the pharmacodynamic properties of the antibody in these species. Cell-based ELISA assays were used to demonstrate that BI 836845 potently neutralizes the ability of IGF-1 and IGF-2 to phosphorylate the human IGF-1R. Similarly, BI 836845 inhibits phosphorylation of IR-A driven by IGF-2. BI 836845 was also shown to completely and potently inhibit IGF bioactivity in human serum samples ex vivo. Pharmacodynamic effects of BI 836845 were studied in growing rats treated intravenously once weekly with 20, 60, or 200 mg/kg antibody. Inhibition of IGF bioactivity as determined by ex vivo IGF-1R phosphorylation potential in the plasma was observed at all dose levels, despite a corresponding increase in total IGF-1 levels. An increase in total IGF-1 levels has also been seen with IGF-1R targeted antibodies in clinical studies and is thought to be due to blockade of a growth hormone mediated physiological feedback mechanism. Treatment with BI 836845 resulted in a marked dose dependent reduction of rat body weight gain at all dose levels, consistent with the known role for IGFs in normal growth and development. BI 836845 potently inhibits the in vitro proliferation of cell lines derived from various cancers, with mesenchymal-derived cancer cell lines being particularly sensitive (EC50 values in the low nanomolar range). In a model of Ewing s sarcoma, using immunodeficient nude mice subcutaneously transplanted with human RD-ES cells, twice-weekly treatment with BI 836845 resulted in partial inhibition of tumor growth. Treatment in combination with rapamycin resulted in improved efficacy at tolerated doses. In conclusion, BI 836845 is a potent IGF ligand neutralizing antibody whose pharmacological profile warrants further investigation in clinical studies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A208." @default.
• W2047815134 created "2016-06-24" @default.
• W2047815134 creator A5007810079 @default.
• W2047815134 creator A5014031976 @default.
• W2047815134 creator A5021970433 @default.
• W2047815134 creator A5042123380 @default.
• W2047815134 creator A5052456593 @default.
• W2047815134 creator A5073798913 @default.
• W2047815134 creator A5076013265 @default.
• W2047815134 date "2011-11-01" @default.
• W2047815134 modified "2023-09-25" @default.
• W2047815134 title "Abstract A208: Pharmacodynamic properties and antitumor efficacy of BI 836845, a fully human IGF ligand neutralizing antibody." @default.
• W2047815134 doi "https://doi.org/10.1158/1535-7163.targ-11-a208" @default.
• W2047815134 hasPublicationYear "2011" @default.
• W2047815134 type Work @default.
• W2047815134 sameAs 2047815134 @default.
• W2047815134 citedByCount "3" @default.
• W2047815134 countsByYear W20478151342012 @default.
• W2047815134 countsByYear W20478151342015 @default.
• W2047815134 countsByYear W20478151342020 @default.
• W2047815134 crossrefType "journal-article" @default.
• W2047815134 hasAuthorship W2047815134A5007810079 @default.
• W2047815134 hasAuthorship W2047815134A5014031976 @default.
• W2047815134 hasAuthorship W2047815134A5021970433 @default.
• W2047815134 hasAuthorship W2047815134A5042123380 @default.
• W2047815134 hasAuthorship W2047815134A5052456593 @default.
• W2047815134 hasAuthorship W2047815134A5073798913 @default.
• W2047815134 hasAuthorship W2047815134A5076013265 @default.
• W2047815134 hasConcept C111113717 @default.
• W2047815134 hasConcept C112705442 @default.
• W2047815134 hasConcept C11960822 @default.
• W2047815134 hasConcept C150903083 @default.
• W2047815134 hasConcept C153911025 @default.
• W2047815134 hasConcept C159654299 @default.
• W2047815134 hasConcept C170493617 @default.
• W2047815134 hasConcept C185592680 @default.
• W2047815134 hasConcept C203014093 @default.
• W2047815134 hasConcept C207001950 @default.
• W2047815134 hasConcept C2775960820 @default.
• W2047815134 hasConcept C2779261636 @default.
• W2047815134 hasConcept C2780689927 @default.
• W2047815134 hasConcept C502942594 @default.
• W2047815134 hasConcept C55493867 @default.
• W2047815134 hasConcept C86803240 @default.
• W2047815134 hasConcept C95444343 @default.
• W2047815134 hasConcept C98274493 @default.
• W2047815134 hasConceptScore W2047815134C111113717 @default.
• W2047815134 hasConceptScore W2047815134C112705442 @default.
• W2047815134 hasConceptScore W2047815134C11960822 @default.
• W2047815134 hasConceptScore W2047815134C150903083 @default.
• W2047815134 hasConceptScore W2047815134C153911025 @default.
• W2047815134 hasConceptScore W2047815134C159654299 @default.
• W2047815134 hasConceptScore W2047815134C170493617 @default.
• W2047815134 hasConceptScore W2047815134C185592680 @default.
• W2047815134 hasConceptScore W2047815134C203014093 @default.
• W2047815134 hasConceptScore W2047815134C207001950 @default.
• W2047815134 hasConceptScore W2047815134C2775960820 @default.
• W2047815134 hasConceptScore W2047815134C2779261636 @default.
• W2047815134 hasConceptScore W2047815134C2780689927 @default.
• W2047815134 hasConceptScore W2047815134C502942594 @default.
• W2047815134 hasConceptScore W2047815134C55493867 @default.
• W2047815134 hasConceptScore W2047815134C86803240 @default.
• W2047815134 hasConceptScore W2047815134C95444343 @default.
• W2047815134 hasConceptScore W2047815134C98274493 @default.
• W2047815134 hasIssue "11_Supplement" @default.
• W2047815134 hasLocation W20478151341 @default.
• W2047815134 hasOpenAccess W2047815134 @default.
• W2047815134 hasPrimaryLocation W20478151341 @default.
• W2047815134 hasRelatedWork W1998587742 @default.
• W2047815134 hasRelatedWork W2035878463 @default.
• W2047815134 hasRelatedWork W2053592362 @default.
• W2047815134 hasRelatedWork W2129738704 @default.
• W2047815134 hasRelatedWork W2167792947 @default.
• W2047815134 hasRelatedWork W2170189640 @default.
• W2047815134 hasRelatedWork W2298675257 @default.
• W2047815134 hasRelatedWork W2886928388 @default.
• W2047815134 hasRelatedWork W4200296455 @default.
• W2047815134 hasRelatedWork W4283766204 @default.
• W2047815134 hasVolume "10" @default.
• W2047815134 isParatext "false" @default.
• W2047815134 isRetracted "false" @default.
• W2047815134 magId "2047815134" @default.
• W2047815134 workType "article" @default.